Share-based Payment Arrangement, Expense of ALPINE IMMUNE SCIENCES, INC. from 31 Dec 2015 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ALPINE IMMUNE SCIENCES, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 31 Mar 2024.
  • ALPINE IMMUNE SCIENCES, INC. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $3,989,000, a 56% increase year-over-year.
  • ALPINE IMMUNE SCIENCES, INC. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $12,067,000, a 22% increase year-over-year.
  • ALPINE IMMUNE SCIENCES, INC. annual Share-based Payment Arrangement, Expense for 2023 was $10,630,000, a 10% increase from 2022.
  • ALPINE IMMUNE SCIENCES, INC. annual Share-based Payment Arrangement, Expense for 2022 was $9,648,000, a 55% increase from 2021.
  • ALPINE IMMUNE SCIENCES, INC. annual Share-based Payment Arrangement, Expense for 2021 was $6,240,000, a 51% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ALPINE IMMUNE SCIENCES, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $12,067,000 $3,989,000 +$1,437,000 +56% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $10,630,000 $2,803,000 +$334,000 +14% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2024 2023 FY
Q3 2023 $10,296,000 $2,654,000 +$99,000 +3.9% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $10,197,000 $2,621,000 +$286,000 +12% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $9,911,000 $2,552,000 +$263,000 +11% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $9,648,000 $2,469,000 +$1,009,000 +69% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 $8,639,000 $2,555,000 +$917,000 +56% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $7,722,000 $2,335,000 +$790,000 +51% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,932,000 $2,289,000 +$692,000 +43% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $6,240,000 $1,460,000 +$511,000 +54% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2024 2023 FY
Q3 2021 $5,729,000 $1,638,000 +$665,000 +68% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $5,064,000 $1,545,000 +$313,000 +25% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $4,751,000 $1,597,000 +$611,000 +62% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $4,140,000 $949,000 +$169,000 +22% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
Q3 2020 $3,971,000 $973,000 +$148,000 +18% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $3,823,000 $1,232,000 +$550,000 +81% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $3,273,000 $986,000 +$232,000 +31% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $3,041,000 $780,000 +$49,000 +6.7% 01 Oct 2019 31 Dec 2019 10-K 17 Mar 2022 2021 FY
Q3 2019 $2,992,000 $825,000 +$281,000 +52% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $2,711,000 $682,000 +$159,000 +30% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $2,552,000 $754,000 +$243,000 +48% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q4 2018 $2,309,000 $731,000 +$422,000 +137% 01 Oct 2018 31 Dec 2018 10-K 18 Mar 2021 2020 FY
Q3 2018 $1,887,000 $544,000 +$315,000 +138% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $1,572,000 $523,000 +$275,000 +111% 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2
Q1 2018 $1,297,000 $511,000 +$459,000 +883% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $838,000 $309,000 +$1,651,000 01 Oct 2017 31 Dec 2017 10-K 30 Mar 2020 2019 FY
Q3 2017 $813,000 $229,000 +$217,000 +1808% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $1,030,000 $248,000 -$452,000 -65% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $578,000 $52,000 -$655,000 -93% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1
Q4 2016 $77,000 $1,342,000 01 Oct 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
Q3 2016 $12,000 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2017 Q3
Q2 2016 $700,000 01 Apr 2016 30 Jun 2016 10-Q 21 Jul 2017 2017 Q2
Q1 2016 $707,000 01 Jan 2016 31 Mar 2016 10-Q 02 May 2017 2017 Q1

ALPINE IMMUNE SCIENCES, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $10,630,000 +$982,000 +10% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2024 2023 FY
2022 $9,648,000 +$3,408,000 +55% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
2021 $6,240,000 +$2,100,000 +51% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2024 2023 FY
2020 $4,140,000 +$1,099,000 +36% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
2019 $3,041,000 +$732,000 +32% 01 Jan 2019 31 Dec 2019 10-K 17 Mar 2022 2021 FY
2018 $2,309,000 +$1,471,000 +176% 01 Jan 2018 31 Dec 2018 10-K 18 Mar 2021 2020 FY
2017 $838,000 +$761,000 +988% 01 Jan 2017 31 Dec 2017 10-K 30 Mar 2020 2019 FY
2016 $77,000 +$61,000 +381% 01 Jan 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
2015 $16,000 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.